Neovasc Plans Next Steps After Thumbs Down From FDA Panel
FDA advisory committee members said the trial population was too small and homogenous and did not establish that Neovasc’s Reducer effectively treats angina.
You may also be interested in...
Neovasc Plans ‘Two Shots On Goal’ For Reducer To Treat Angina
Neovasc’ COO Bill Little talked to Medtech Insight about the company’s plans to develop its Reducer transcatheter device to treat cardiac angina associated with or without obstructive coronary disease.
Neovasc Maintains Investor Confidence Despite FDA Struggles; Sells $72M In Stock
Despite a recent unfavorable FDA advisory panel for its Reducer coronary sinus device, some investors showed their faith in the Canadian company by buying 36 million shares.
FDA Schedules Advisory Panel To Review Neovasc’s Angina Treatment
The US FDA's Circulatory System Devices Panel will meet on 27 October to evaluate Neovasc’s Reducer device, a minimally invasive treatment for drug-refractory angina.